Literature DB >> 4042524

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.

A Küpfer, R A Branch.   

Abstract

The 8-hour urinary recovery of 4-hydroxy-mephobarbital has been measured after oral administration of racemic mephobarbital (90 mg) in 17 extensive (EM) and six poor (PM) metabolizer phenotypes of mephenytoin. The recovery of this metabolite was measurable in every EM and ranged from 2.5% to 48% (10.9% +/- 1.9% of dose), but was not detected in any PM (less than 1% of dose). In EMs, the 8-hour urine recovery of 4-OH-mephobarbital after mephobarbital was approximately half that of 4-OH-mephenytoin over the same time after mephenytoin administration. One EM received similar doses of R- and S-mephobarbital on separate occasions. Urinary recovery of 4-OH-mephobarbital was 33% and less than 1%, respectively. These results suggest that mephobarbital is stereoselectively hydroxylated by the same drug metabolizing enzyme that is responsible for the stereoselective aromatic hydroxylation of mephenytoin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042524     DOI: 10.1038/clpt.1985.196

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.

Authors:  Yumiko Ohkubo; Akihito Ueta; Naoki Ando; Tetsuya Ito; Sachiko Yamaguchi; Kantaro Mizuno; Satoshi Sumi; Tohru Maeda; Daiju Yamazaki; Yukihisa Kurono; Shinji Fujimoto; Hajime Togari
Journal:  J Hum Genet       Date:  2005-11-24       Impact factor: 3.172

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation.

Authors:  E Perucca; O Dulac; S Shorvon; T Tomson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.

Authors:  M L Dahl-Puustinen; C Alm; L Bertilsson; I Christenson; J Ostman; E Thunberg; I Wikström
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 5.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 8.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 9.  Variability in drug metabolism: importance of genetic constitution.

Authors:  J H Schellens; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

10.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

Authors:  A Drøhse; L Bathum; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.